Prices delayed by at least 15 minutes | Print
TRANSGENE (TNG)
TRANSGENEOpen
€1.346
Previous close
€1.346
Trade high
€1.346
Volume
50,816
Year high
€2.55
Year low
€1.03
Dividend yield
-
Market capitalisation
€129.09 mn
P/E ratio
10.79
ISIN
FR0005175080
This share can be held in a Dealing accountISALifetime ISAJISASIPP
Share price
Company profile
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of itsoperations is located in France.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.